Univariate and multivariate analyses
| Variables . | Categories . | Grades 2-4 acute GVHD . | Leukemia/MDS progression/recurrence . | TRM . | Event-free survival . | Overall survival . |
|---|---|---|---|---|---|---|
| Univariate analyses (no. of patients with an event) | ||||||
| Disease status* | Standard vs high risk | NS | P < .001 (10/40 vs 27/43) | P = .035 (4/40 vs 12/43) | P < .001 (15/40 vs 39/43) | P < .001 (15/40 vs 37/43) |
| Previous allogeneic HCT | No vs yes | NS | P = .018 (28/71 vs 9/12) | NS | P = .015 (43/71 vs 11/12) | NS |
| Donor age, years | ≤ 40 vs > 40 | P = .048 (7/53 vs 9/30) | NS | NS | NS | NS |
| Donor-patient HLA allele mismatch | 3/8 or less vs 4/8 | P = .012 (1/27 vs 9/23) | NS | NS | NS | NS |
| Multivariate analysis [hazard ratio (95% CI)] | ||||||
| Disease status | Standard vs high risk | NS | P < .001 [3.56 (1.81-7.00)] | P = .040 [3.17 (1.05-9.57)] | P < .001 [5.53 (2.99-10.21)] | P < .001 [4.66 (2.52-8.61)] |
| Donor age, years | ≤ 40 vs > 40 | P = .048 [2.64 (1.01-6.94)] | NS | NS | NS | NS |
| Previous allogeneic HCT | No vs yes | NS | NS | NS | P = .012 [2.41 (1.22-4.78)] | NS |
| Variables . | Categories . | Grades 2-4 acute GVHD . | Leukemia/MDS progression/recurrence . | TRM . | Event-free survival . | Overall survival . |
|---|---|---|---|---|---|---|
| Univariate analyses (no. of patients with an event) | ||||||
| Disease status* | Standard vs high risk | NS | P < .001 (10/40 vs 27/43) | P = .035 (4/40 vs 12/43) | P < .001 (15/40 vs 39/43) | P < .001 (15/40 vs 37/43) |
| Previous allogeneic HCT | No vs yes | NS | P = .018 (28/71 vs 9/12) | NS | P = .015 (43/71 vs 11/12) | NS |
| Donor age, years | ≤ 40 vs > 40 | P = .048 (7/53 vs 9/30) | NS | NS | NS | NS |
| Donor-patient HLA allele mismatch | 3/8 or less vs 4/8 | P = .012 (1/27 vs 9/23) | NS | NS | NS | NS |
| Multivariate analysis [hazard ratio (95% CI)] | ||||||
| Disease status | Standard vs high risk | NS | P < .001 [3.56 (1.81-7.00)] | P = .040 [3.17 (1.05-9.57)] | P < .001 [5.53 (2.99-10.21)] | P < .001 [4.66 (2.52-8.61)] |
| Donor age, years | ≤ 40 vs > 40 | P = .048 [2.64 (1.01-6.94)] | NS | NS | NS | NS |
| Previous allogeneic HCT | No vs yes | NS | NS | NS | P = .012 [2.41 (1.22-4.78)] | NS |
NS indicates not significant.
Standard risk was defined as patients with acute leukemia in CR1, CR2, or CR3 at the time of transplantation or with low-risk MDS (ie, refractory anemia, refractory anemia with ring sideroblasts, or refractory cytopenia with multilineage dysplasia). Otherwise, patients were defined as high risk.